Initial prices for brand-name prescription drugs climbed steadily over two decades, with no immediate slowdown following the Inflation Reduction Act.1


RT’s Three Key Takeaways:

  1. Persistent Price Growth: Initial launch prices for new prescription drugs rose by an adjusted 7.82% annually prior to federal reform and maintained that trajectory without significant deviation afterward.
  2. Higher Costs for Chronic Care: Therapies indicated for chronic conditions experienced launch price growth nearly 9% faster per year than acute medications, while cell and gene therapies commanded the highest baseline costs.
  3. Policy Implications for Healthcare: Authors noted that while pharmaceutical manufacturers did not accelerate launch prices in direct response to federal Medicare negotiation rules, additional legislative measures may be required to protect patient access and manage out-of-pocket healthcare costs.


Launch prices for newly approved prescription drugs in the US increased steadily between 2008 and 2025, with no measurable change in trends following the passage of the federal Inflation Reduction Act (IRA), according to a study published in JAMA.1

Total US prescription drug spending reached $800 billion in 2024, heavily driven by the initial costs set for brand-name therapies.1 While policymakers designed the 2022 law to allow Medicare to negotiate prices for certain high-spend drugs later in their life cycle and penalize post-launch price increases exceeding inflation, analysts had questioned whether manufacturers would respond by raising initial list prices to protect long-term revenues.1

Researchers analyzed 643 novel medications approved by the USFDA between 2008 and 2025, representing 65% of the 991 newly approved products during that timeframe.1 For each drug, investigators calculated wholesale acquisition costs normalized to an annual treatment cost or a standard course of treatment.1

Significant Shifts in Baseline Drug Costs

According to the study findings, median launch prices increased from $38,857 between 2008 and 2013 to $254,213 between 2020 and 2025.1

Across specific therapeutic categories, costs varied substantially:

  • Prices were 9.56 times higher for cell and gene therapies than for small-molecule drugs.
  • Drugs intended for chronic use entered the market at prices 6.06 times higher than acute treatments.
  • Medications with rare disease designations had launch prices 3.82 times higher than therapies without orphan status.1

Overall unadjusted mean launch prices increased by 15.89% per year across the full cohort.1 In an adjusted interrupted time series model accounting for route of administration, indication, expedited review pathways, and biologic status, prices rose by 7.82% annually before the IRA passed in September 2022.1

Post-Reform Trends and Clinical Impact

Following the enactment of the law, researchers observed no statistically significant change in either the level or trajectory of launch prices. A subgroup evaluation focused specifically on oncology products yielded similar results.1

Subgroup models revealed that prices increased 8.95% per year more quickly for chronic medications compared with acute therapies and 6.63% per year more quickly for rare disease designations compared with common indications.1

Conversely, medications approved through expedited FDA pathways experienced price increases that were 5.65% per year slower than those reviewed under nonexpedited processes.1

The study authors noted that manufacturer list prices directly influence access to therapy, patient coinsurance obligations, and broader budgetary strain across healthcare systems.1 While findings showed no empirical evidence that pharmaceutical makers inflated launch prices specifically to preempt IRA negotiation provisions during the initial three-year post-statute window, baseline launch prices continue to surpass general inflation.1

The researchers suggested that to curb long-term expenditure and maintain patient access to novel therapies, federal policymakers could explore extending price negotiation authorities to new medications shortly after launch or expanding negotiated rates to commercial plans.1


Reference

  1. Shanmugam H, Kesselheim AS, McGuire M, Rome BN. Prescription Drug Launch Price Trends Before and After the Inflation Reduction Act. JAMA. Published online September 30, 2026. doi:10.1001/jama.2026.17742